Latest BSX news

Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?

Zacks Investment Research · Mon, 21 Sep 2026 10:10:50 -0400

BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.

New Strong Sell Stocks for September 21st

Zacks Investment Research · Mon, 21 Sep 2026 07:46:10 -0400

AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.

BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?

Zacks Investment Research · Thu, 17 Sep 2026 10:11:14 -0400

Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.

New Strong Sell Stocks for September 16th

Zacks Investment Research · Wed, 16 Sep 2026 05:02:09 -0400

AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.

Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade)

Seeking Alpha · Tue, 15 Sep 2026 07:30:35 -0400

Boston Scientific is upgraded to 'Strong Buy' as market overreaction creates an attractive entry point for long-term investors. BSX trades at a forward P/E of 13.1, well below its historical average, despite robust profitability and solid Q2 2026 results. Growth headwinds from WATCHMAN and electrophysiology are offset by strong Interventional Cardiology and Vascular Therapies momentum.

Boston Scientific Leans on Acquisitions to Drive Long-Term Growth

Zacks Investment Research · Mon, 14 Sep 2026 11:40:53 -0400

BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.

Boston Scientific: $43 Finally Prices In A Bad 2026

Seeking Alpha · Fri, 11 Sep 2026 10:57:36 -0400

Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns.

Market information is provided for research and visualization and is not investment advice.